CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 96 enrolled
Drug / intervention
HSPPC-96 +1 morebiological
Likely dose
HSPPC-96 25 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00293423
NCT00293423Phase 2Completed
CompareCT.gov

Phase I/II Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine for Patients With Recurrent High Grade Glioma

University of California, San Francisco·interventional·Posted Feb 17, 2006·Updated May 13, 2021

In Brief

A Phase 2 clinical trial evaluating HSPPC-96 and Standard Surgical Resection for Brain and Central Nervous System Tumors. Completed, enrolled 96 participants across 3 sites.

Detailed Summary

Vaccines made from a person's tumor cells, such as gp96 heat shock protein-peptide complex, may help the body build an effective immune response to kill tumor cells. This phase I/II trial is studying the side effects and best dose of gp96 heat shock protein-peptide complex vaccine to see how well it works in treating patients with recurrent or progressive high-grade glioma over time.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBrain and Central Nervous System Tumors
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), Agenus Inc., American Brain Tumor Association

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 17, 2006
Enrollment StartNov 18, 2005
Primary CompletionJan 12, 2013
TodayJul 2, 2026
Enrollment to primary: 7.1 yearsPosted 20.4 years ago

Interventions

HSPPC-96biological

25 mcg

Standard Surgical Resectionprocedure

Patients will undergo standard surgical resection of intracranial tumor